AB08-1mg / 询价
- 关联产品
- 客服电话
- 技术支持
Anti-B7-H3 Antibody (Enoblituzumab Biosimilar)
Human/Cynomolgus
B7-H3
Human IgG1-Kappa
Unconjugated
protein A
0.2 μM filtered
PBS, 10% glycerol (pH 7.4)
Less than 1 EU per μg by the LAL method.
（Recommended Dilution Buffer）
PBS (pH 7.4), contains no stabilizers or preservatives.
<p style="line-height: 25px;">> 95% as determined by Bis-Tris PAGE<br />> 90% as determined by HPLC</p>
<p style="line-height: 25px;">Valid for 12 months from date of receipt when stored at -80°C.<br />Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.</p>
ELISA
B7-H3, a member of the B7 family of immunomodulatory molecules, is overexpressed in a wide range of solid cancers. B7-H3 binds to activated T cells via an as yet unidentified receptor. In assays using sub-optimal amount so anti-CD3 stimulation, 2Ig‑B7‑H3 enhances T cell proliferation, T cell interferon-gamma (IFN-gamma) production, and cytotoxic T cells induction.
Fodstad O, Tekle C, Chen Y W. The Immunoregulatory Protein Human B7H3 is a Tumor-Associated Antigen that Regulates Tumor Cell Migration and Invasion[J]. Current Cancer Drug Targets, 2008, 8(5)
(2)Du H, Hirabayashi K, Ahn S, et al. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells[J]. Cancer Cell, 2019, 35(2).
